Effects of supplementation for liver disease on compensated cirrhotic patients: a randomized, double-blind, placebo-controlled trial
- Conditions
- HCV-related liver disease
- Registration Number
- JPRN-UMIN000012815
- Lead Sponsor
- Kurume University School of Medicine
- Brief Summary
There was no significant difference in platelet count, albumin level, and HOMA-IR value between the supplement and control groups. In the supplement group, the BTR and zinc levels were significantly increased compared with the placebo group . No significant differences were observed in AFP levels between the groups in the whole analysis. However, a stratification analysis showed a significant reduction in delta AFP levels in the supplement group, with elevated AFP levels compared with the other groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
1. Subjects who had taken the supplement 2. Subjects who were treated with BCAA-containing agents 3. Subjects who were treated with antidiabetic agents 4. Subjects who were treated with zinc-containing agent or supplement 5. Subjects with obstruction of gut 6. Subjects with hepatic encepharlopathy 7. Subjects with severe hepato-renal diseases 8. Subjects with hepatocellular carcinoma 9. Subjects with risky esophageal varices 10. Subjects with other liver diseases including hepatitis B-related liver disease, alcoholic liver disease, non-alcoholic steatohepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, haemochromatosis, Wilson disease 11. HCV-infected subjects who are or will be treated with interferon thrapy 12. Subject with any type of severe extra-hepatic diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method